{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cellulose+Powder",
    "query": {
      "intervention": "Cellulose Powder"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 55,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cellulose+Powder&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T09:48:44.973Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01723397",
      "title": "Effect of Nasaleze on Nasal Challenge With Allergen",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Allergic Rhinitis"
      ],
      "interventions": [
        {
          "name": "Nasaleze Spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo spray",
          "type": "OTHER"
        },
        {
          "name": "Allergen",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 14,
      "start_date": "2012-11",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2017-01-02",
      "last_synced_at": "2026-09-03T09:48:44.973Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01723397"
    },
    {
      "nct_id": "NCT05510115",
      "title": "Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Polycystic Kidney, Autosomal Dominant"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 50,
      "start_date": "2022-11-18",
      "completion_date": "2026-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-09-03T09:48:44.973Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05510115"
    },
    {
      "nct_id": "NCT06516744",
      "title": "A Single Group Study to Evaluate the Efficacy of Bye Bye Bloat Capsules in Relieving Bloating and Promoting Healthy Digestion.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Digestive Health",
        "Digestion"
      ],
      "interventions": [
        {
          "name": "Bye Bye Bloat Capsules",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Love Wellness",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2024-02-08",
      "completion_date": "2024-04-20",
      "has_results": false,
      "last_update_posted_date": "2024-07-24",
      "last_synced_at": "2026-09-03T09:48:44.973Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06516744"
    },
    {
      "nct_id": "NCT01154101",
      "title": "Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "SRT2104",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sirtris, a GSK Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 40,
      "start_date": "2010-06-07",
      "completion_date": "2011-11-09",
      "has_results": true,
      "last_update_posted_date": "2017-10-13",
      "last_synced_at": "2026-09-03T09:48:44.973Z",
      "location_count": 8,
      "location_summary": "St Louis, Missouri • New York, New York • Portland, Oregon + 4 more",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01154101"
    },
    {
      "nct_id": "NCT03403387",
      "title": "Effects of GlutenShield, a Prebiotic, Probiotic, and Enzyme Supplement, on the Gut Microbiome of Adults With GI Symptoms",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Gastrointestinal Symptoms"
      ],
      "interventions": [
        {
          "name": "GlutenShield",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "East Tennessee State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2018-01-22",
      "completion_date": "2018-03-31",
      "has_results": false,
      "last_update_posted_date": "2018-01-18",
      "last_synced_at": "2026-09-03T09:48:44.973Z",
      "location_count": 1,
      "location_summary": "Johnson City, Tennessee",
      "locations": [
        {
          "city": "Johnson City",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03403387"
    },
    {
      "nct_id": "NCT07606664",
      "title": "Fezolinetant and Vascular Health and Brain Health",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Menopause Hot Flashes"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Fezolinetant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rebecca Thurston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 65 Years · Female only"
      },
      "enrollment_count": 220,
      "start_date": "2026-09-25",
      "completion_date": "2029-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-09-03T09:48:44.973Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07606664"
    },
    {
      "nct_id": "NCT02017249",
      "title": "Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "arginine in powder form",
          "type": "DRUG"
        },
        {
          "name": "Silica and cellulose placebo powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inova Health Care Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2014-03",
      "completion_date": "2015-10-06",
      "has_results": false,
      "last_update_posted_date": "2019-09-16",
      "last_synced_at": "2026-09-03T09:48:44.973Z",
      "location_count": 1,
      "location_summary": "Fairfax, Virginia",
      "locations": [
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02017249"
    },
    {
      "nct_id": "NCT05713799",
      "title": "Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Insulin Resistance",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Alpha-lipoic acid",
          "type": "DRUG"
        },
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2026-09-07",
      "completion_date": "2030-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-09-03T09:48:44.973Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05713799"
    },
    {
      "nct_id": "NCT06146374",
      "title": "Safety Study of SLV213 for the Treatment of COVID-19.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Placebo for SLV213",
          "type": "OTHER"
        },
        {
          "name": "SLV213",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 16,
      "start_date": "2024-04-09",
      "completion_date": "2024-07-08",
      "has_results": true,
      "last_update_posted_date": "2025-07-22",
      "last_synced_at": "2026-09-03T09:48:44.973Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06146374"
    },
    {
      "nct_id": "NCT01848340",
      "title": "An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV-associated Lipodystrophy Syndrome"
      ],
      "interventions": [
        {
          "name": "GSK1265744B (sodium salt) containing 14C-GSK1265744B",
          "type": "DRUG"
        },
        {
          "name": "150 mg GSK1265744B",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 16,
      "start_date": "2013-05",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2013-11-04",
      "last_synced_at": "2026-09-03T09:48:44.973Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01848340"
    }
  ]
}